NewslettersIntestinal Cell NewsOrganovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug CandidatesBy Bob - November 18, 20220282Organovo Holdings, Inc. announced that it has successfully advanced the use of its first inflammatory bowel disease model and has achieved the next milestone, target validation.[Organovo Holdings, Inc.]Press Release